

Practical Perspectives on the Current and Future Management of Immune Thrombocytopenia — What Happened at ASH 2025? Microlearning Activity 3

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following thrombopoietin receptor agonists is a potent iron chelator?**
  - Avatrombopag
  - Eltrombopag**
  - Romiplostim
- 2. Which type of fibrosis has been reported with thrombopoietin receptor agonists?**
  - Reticulin fibrosis
  - Collagen fibrosis**
  - Both reticulin and collagen fibrosis
- 3. High-dose dexamethasone pulse therapy has demonstrated which outcome when compared to conventional prednisone for patients with previously untreated immune thrombocytopenia (ITP)?**
  - A significantly higher overall response rate
  - A significantly lower overall response rate
  - No difference in overall response rate**
- 4. What is the approximate probability of success of a splenectomy for a patient with ITP whose disease has not responded to rituximab or to a thrombopoietin receptor agonist?**
  - 8% to 12%
  - 25% to 32%
  - 40% to 45%**
  - 72% to 78%